Prilosec patent litigation
This article was originally published in The Tan Sheet
New York federal court upholds validity of AstraZeneca's two formulation patents and rules that three of four companies involved in Rx omeprazole patent litigation - Andrx, Dr. Reddy's and Genpharm - infringe those patents. However, Schwarz Pharma's product does not infringe, Judge Barbara Jones says in Oct. 11 ruling. Decision is not expected to impact AstraZeneca/P&G's eventual OTC sale of the proton pump inhibitor. OTC Prilosec would carry a claim for prevention of frequent heartburn - which differs from the approved Rx indication - and is expected to garner three-year Hatch/Waxman exclusivity. P&G anticipates FDA approval of the OTC switch in first quarter of 2003...
You may also be interested in...
Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.